VYNE Therapeutics Inc.
VYNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $501 | $424 | $477 | $931 |
| % Growth | 18.2% | -11.1% | -48.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $501 | $424 | $477 | $931 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $30,946 | $16,307 | $18,385 | $19,543 |
| G&A Expenses | $13,192 | $13,375 | $16,387 | $0 |
| SG&A Expenses | $13,192 | $13,375 | $16,387 | $20,299 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $44,138 | $29,682 | $34,772 | $39,842 |
| Operating Income | -$43,637 | -$29,258 | -$34,295 | -$38,911 |
| % Margin | -8,710% | -6,900.5% | -7,189.7% | -4,179.5% |
| Other Income/Exp. Net | $3,834 | $1,386 | $363 | -$4,849 |
| Pre-Tax Income | -$39,803 | -$27,872 | -$33,932 | -$43,760 |
| Tax Expense | $4 | $0 | $13 | $448 |
| Net Income | -$39,834 | -$28,452 | -$23,210 | -$73,329 |
| % Margin | -7,950.9% | -6,710.4% | -4,865.8% | -7,876.4% |
| EPS | -0.94 | -2.77 | -10.65 | -25.65 |
| % Growth | 66.1% | 74% | 58.5% | – |
| EPS Diluted | -0.94 | -2.77 | -10.65 | -25.65 |
| Weighted Avg Shares Out | 42,589 | 10,273 | 3,186 | 2,859 |
| Weighted Avg Shares Out Dil | 42,589 | 10,273 | 3,186 | 2,859 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $5,610 |
| Depreciation & Amortization | $4 | $0 | $72 | $109 |
| EBITDA | -$43,633 | -$29,258 | -$34,223 | -$38,802 |
| % Margin | -8,709.2% | -6,900.5% | -7,174.6% | -4,167.8% |